Clinical	clinical	O	O	O	O
experiences	experiences	O	O	O	O
in	in	O	O	O	O
an	an	O	O	O	O
open	open	O	O	O	O
and	and	O	O	O	O
a	a	O	O	O	O
double-blind	double-blind	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
total	total	O	O	O	O
of	of	O	O	O	O
sixty	sixty	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
trated	trated	O	O	O	O
with	with	O	O	O	O
bromperidol	bromperidol	O	O	OTHERS	I
first	first	O	O	O	O
in	in	O	O	O	O
open	open	O	O	O	O
conditions	conditions	O	O	O	O
(	(	O	O	O	O
20	20	O	O	O	O
patients	patients	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
then	then	O	O	O	O
on	on	O	O	O	O
a	a	O	O	O	O
double	double	O	O	O	O
blind	blind	O	O	OTHERS	I
basis	basis	O	O	O	O
(	(	O	O	O	O
40	40	O	O	O	O
patients	patients	O	O	O	O
)	)	O	O	O	O
with	with	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
the	the	O	O	O	O
reference	reference	O	O	O	O
substance	substance	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
open	open	O	O	O	O
study	study	O	O	O	O
lasted	lasted	O	O	O	O
for	for	O	O	O	O
four	four	O	O	O	O
weeks	weeks	O	O	O	O
;	;	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
was	was	O	O	O	O
administrated	administrated	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
form	form	O	O	O	O
of	of	O	O	O	O
1	1	O	O	O	O
mg	mg	O	O	OTHERS	I
tablets	tablets	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
daily	daily	O	O	O	O
dose	dose	O	O	O	O
(	(	O	O	O	O
initial	initial	O	O	O	O
dose	dose	O	O	O	O
:	:	O	O	O	O
1	1	O	O	O	O
mg	mg	O	O	OTHERS	I
;	;	O	O	O	O
mean	mean	O	O	O	O
dose	dose	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
end	end	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
trial	trial	O	O	O	O
:	:	O	O	O	O
4.47	4.47	O	O	O	O
mg	mg	O	O	OTHERS	I
)	)	O	O	O	O
was	was	O	O	O	O
always	always	O	O	O	O
administered	administered	O	O	O	O
in	in	O	O	O	O
one	one	O	O	O	O
single	single	O	O	O	O
dose	dose	O	O	O	O
.	.	O	O	O	O

Nineteen	nineteen	O	O	O	O
patients	patients	O	O	O	O
finished	finished	O	O	O	O
the	the	O	O	O	O
trial	trial	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
18	18	O	O	O	O
cases	cases	O	O	O	O
the	the	O	O	O	O
therapeutic	therapeutic	O	O	O	O
result	result	O	O	O	O
was	was	O	O	O	O
considered	considered	O	O	O	O
very	very	O	O	O	O
good	good	O	O	O	O
to	to	O	O	O	O
good	good	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
results	results	O	O	O	O
were	were	O	O	O	O
confirmed	confirmed	O	O	O	O
by	by	O	O	O	O
statistical	statistical	O	O	O	O
analysis	analysis	O	O	O	O
.	.	O	O	O	O

Nine	nine	O	O	O	O
patients	patients	O	O	O	O
exhibited	exhibited	O	O	O	O
mild	mild	O	O	O	O
to	to	O	O	O	O
moderate	moderate	O	O	O	O
extrapyramidal	extrapyramidal	O	O	OTHERS	I
concomitant	concomitant	O	O	OTHERS	I
symptoms	symptoms	O	O	OTHERS	I
;	;	O	O	O	O
no	no	O	O	O	O
other	other	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
detailed	detailed	O	O	O	O
laboratory	laboratory	O	O	O	O
tests	tests	O	O	O	O
and	and	O	O	O	O
evaluations	evaluations	O	O	O	O
of	of	O	O	O	O
various	various	O	O	O	O
quantitative	quantitative	O	O	O	O
and	and	O	O	O	O
qualitative	qualitative	O	O	O	O
tolerability	tolerability	O	O	O	O
parameters	parameters	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
indicative	indicative	O	O	O	O
of	of	O	O	O	O
toxic	toxic	O	O	O	O
effects	effects	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
double	double	O	O	O	O
blind	blind	O	O	OTHERS	I
study	study	O	O	O	O
with	with	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
both	both	O	O	O	O
substances	substances	O	O	O	O
were	were	O	O	O	O
found	found	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
highly	highly	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
psychotic	psychotic	O	O	OTHERS	I
syndromes	syndromes	O	O	OTHERS	I
belonging	belonging	O	O	OTHERS	I
predominantly	predominantly	O	O	OTHERS	I
to	to	O	O	OTHERS	I
the	the	O	O	OTHERS	I
schizophrenia	schizophrenia	O	DISEASE	OTHERS	I
group	group	O	O	OTHERS	I
.	.	O	O	O	O

Certain	certain	O	O	O	O
clues	clues	O	O	O	O
,	,	O	O	O	O
including	including	O	O	O	O
the	the	O	O	O	O
onset	onset	O	O	O	O
of	of	O	O	O	O
action	action	O	O	O	O
,	,	O	O	O	O
seem	seem	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
indicative	indicative	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
superiority	superiority	O	O	O	O
of	of	O	O	O	O
bromperidol	bromperidol	O	O	OTHERS	I
.	.	O	O	O	O

No	no	O	O	O	O
differences	differences	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
with	with	O	O	O	O
respect	respect	O	O	O	O
to	to	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
and	and	O	O	O	O
general	general	O	O	O	O
tolerability	tolerability	O	O	O	O
.	.	O	O	O	O

